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COOPERATIVE REGULATION OF AUTOPHAGY BY ONCOGENIC PI3-




Lung cancer is the leading cause of cancer death worldwide with 2.2 million new 
cases diagnosed and 1.8 million deaths per year. Lung squamous cell carcinoma (LSCC) 
is an aggressive histological subtype of non-small cell lung cancers (NSCLC), which is 
strongly associated with cigarette smoking and exposure to environmental pollutants. In 
collaboration with the Computational Biomedicine group at Boston University, we 
identified several putative cancer driver mutations in benign premalignant lung tumors, 
extracted from upper bronchial airway epithelium. The gene mutations from 
premalignant tumors are thought to initiate neoplasia but cannot promote malignancy 
independently. It is hypothesized that additional cooperating mutations  will have a 
compounding effect on tumorigenesis if co-expressed in the same tumor cell. We used 
cancer genomics data from LSCC primary tumors in the Cancer Genome Atlas (TCGA) 
database to identify lung pre-malignancy associated genes that are significantly co-
mutated. Two of the identified mutant genes, PIK3CA and NFE2L2, were shown to co-
occur at a statistically significant rate in LSCC primary tumors. 
The PIK3CA gene encodes the PI3K lipid kinase, which regulates the AKT and 






the product of NFE2L2 gene, is a transcription factor that regulates the antioxidant 
response, playing a protective role against oxidizing cellular damage. NRF2 promotes the 
transcription of key proteins in the antioxidant response such as glutathione S transferase 
and NADPH oxidase. NRF2 is normally subject to ubiquitin-mediated degradation, 
which is regulated by the KEAP1 protein. Loss of function KEAP1 gene mutations are 
common in lung cancer. When cells are exposed to oxidizing agents, KEAP1 is modified 
by these agents, resulting in release and stabilization of NRF2, and the subsequent 
transcription of antioxidant response genes. 
 Studies of PI3K and NRF2, and their downstream effectors have shown that both 
the PI3K/AKT/mTOR and NRF2/KEAP1 signaling pathways control autophagy, which 
is a catabolic process that regulates the recycling of macromolecules under conditions of 
nutrient deprivation. PI3K and NRF2 both control the activity of the SQSTM1/p62 
protein, which plays a major role in autophagic degradation of cargo proteins. Autophagy 
has been implicated as a tumor suppressive mechanism. Both PI3K and NRF2 are known 
to inhibit autophagy in lung cancer cells. Based on the significant frequency of co-
occurrence of PIK3CA and NFE2L2 gene mutations in pre-malignant LSCC lesions, we 
hypothesize that PI3K and NRF2 cooperate to inhibit autophagy to promote LSCC 
progression. 
 To test our hypothesis, we co-expressed mutant forms of PIK3CA (E545K) and 
NFE2L2 (T80K) into a non-transformed Human Bronchial Epithelial Cell line (HBEC-






expression as well as downstream AKT activation and markers of autophagy pathway 
activation. mTORC1 is an effector of PI3K and plays a central role in the inhibition of 
autophagy through the PI3K/AKT/mTOR signaling network. Therefore, we performed 
Western Blot analysis of  samples treated with the mTORC1 inhibitor Everolimus to 
compare the effects of mTORC1 inhibition on autophagy activation in control, single 
PIK3CA, NFE2L2 and double mutant HBEC3-KT cells. We observed significant 
suppression of autophagy in the PI3K/NRF2 double mutant cells. Moreover, the studies 
also showed that the double mutant cells are more sensitive to anti-proliferative effects of 
Everolimus compared to control and single mutant cells. 
Taken together, our studies show that PIK3CA and NFE2L2 mutations cooperate 
to hyperactivate the AKT kinase and to suppress autophagy pathway activation. This 
represents a key mechanism of the malignant transformation of benign premalignant 
LSCC lesions. This warrants further research into the cooperation between PI3K and 
NRF2 in lung cancer pathogenesis. Our results have important implications both for 
diagnosis and treatment of LSCC. Though many important advances in the treatment of 
lung cancer have been made over the past few decades including the use of tyrosine 
kinase inhibitors (TKIs) such as Erlotinib, there is still much to understand about the 
biology and mechanisms of the disease.1 Blockers of the T-cell checkpoint, such as anti-
PD-1 drugs are currently FDA-approved first lines of therapy for NSCLC.  In addition, 
immunotherapy has shown some efficacy in lung cancer patients.2 Our studies provide 






treatment of  LSCC.3 Since mTORC1 inhibitors cause robust inhibition of 
PIK3CA/NFE2L2 double mutant cell proliferation, future studies will be aimed at testing 
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Overview of Non-Small Cell Lung Cancer (NSCLC)  
The lungs are a pair of spongy, air-filled organs on either side of the chest. Air is 
initially inhaled into the trachea which conducts air into the lungs via the bronchi. The 
bronchi divide into smaller bronchioles and eventually end in single cell sacs called 
alveoli. The lung’s main function is to oxygenate red blood cells in the blood. Lungs also 
maintain blood pH in the body by increasing or decreasing the amount of carbon dioxide 
exhaled, and filter out small gas bubbles in the bloodstream.   
Lung cancer is the leading worldwide cause of cancer death with only a 16% five 
year survival rate.4  According to the World Health Organization, in 2018 lung cancer 
was responsible for 2.1 million deaths and is projected to increase to 3.3 million deaths 
per year by 2040.5 Lung cancer has a much lower survival rate than most other epithelial 
malignancies. One reason for this is that the lung tissue is uniquely susceptible to 
tumorigenesis as it is constantly exposed to environmental toxins and airborne 
carcinogens.6 Though the most common aetiology for lung cancers is smoking tobacco, 
the prevalence of lung cancers in non-smokers is on the rise due to exposure to 
carcinogens in pollution. Pollutants containing polycyclic aromatic hydrocarbon 
compounds are known to cause oxidative stress and inflammation.4  As the concern with 
environmental pollution grows, lung cancer is not only a risk for current and former 






The histological subtype, non-small cell lung cancers, accounts for 85% of lung 
cancer diagnoses. This includes squamous cell carcinomas, adenocarcinomas and large 
cell carcinomas.6 Therefore finding potential therapeutics that target NSCLC is of 
primary importance to reducing the cancer burden. Though many important 
advancements in the treatment of NSCLC have been made over the past few decades 
including the use of tyrosine kinase inhibitors (TKIs), there is still much to understand 
about the biology and mechanisms of the disease.   
This thesis explores the role of two oncogenes commonly found in human pre-
neoplastic NSCLC squamous tumors, PIK3CA and NFE2L2, in the transition pre-
malignant human bronchial epithelial cells (HBEC) into a transformed and malignant 
state. PIK3CA encodes the PI3K alpha protein, which promotes mitogenic and cell 
survival signaling pathways. NFE2L2 encodes the NRF2 transcription factor, which 
regulates expression of anti-oxidant response genes. Using genomics data from the 
Cancer Genome Atlas (TCGA/cBioportal), we determined that PIK3CA and NFE2L2 
gene mutations are found to be mutually co-occurring in squamous lung cancers, at a 
high level of statistical significance (log2 Odds Ratio = 1.648; p < 0.001). Based on this 
observation, our central hypothesis is that PIK3CA and NFE2L2 activating gene 
mutations act cooperatively to promote cancer malignancy. We further hypothesize that 
the mutant forms of PI3Kα and NRF2 cooperate to cause increased inhibition of the 






PI3Kα and NRF2 is of vital importance to directing the search for potential cancer 
therapeutics to treat lung squamous cell carcinoma (LSCC). 
The PI3K/AKT/mTORC1 Signaling Pathway   
 
Figure 1: Schematic representation of the PI3K/AKT/mTOR Signaling Network. PI3K is recruited to 
the plasma membrane by RTKs and phosphorylates PIP3 which recruits PDK1 to phosphorylate AKT. 
Phosphorylated AKT inhibits TSC2 via phosphorylation preventing the inactivation of the small G 
protein, Rheb and allowing it to accumulate in its GTP-bound state. Rheb-GTP  indirectly activates 
mTORC1.  
 
Phosphoinositide 3-kinase (PI3K) is a lipid kinase composed of a catalytic subunit 
(p110) and regulatory subunit (p85). PI3K initiates a signal transduction cascade that 
enhances cell growth, survival and metabolism by enhancing cellular replication and 
reducing growth inhibition and apoptosis.7 Oncogenic PIK3CA mutations, including 






of its regulatory and catalytic subunits leading to enhanced signaling and cellular 
transformation.8,9  
The PI3K complex is activated and recruited to the plasma membrane by receptor 
tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR).10  At the 
plasma membrane it mediates the phosphorylation of phospholipid phosphatidylinositol 
4,5 bisphosphate at the 3 position of the inositol ring and converts it to 
phosphatidylinositol trisphosphate (PIP3). PIP3 then functions as a second messenger and 
controls processes related to cell survival, growth, morphology, and motility by recruiting 
proteins with pleckstrin homology (PH) domains such as PDK1 and serine/threonine 
kinase AKT to the plasma membrane. There PDK1 activates AKT, also known as protein 
kinase B, by phosphorylation. (Figure 1)7 
AKT is an important downstream effector of PI3K signaling. It is fully activated 
by mTOR-RICTOR kinase complex (mTORC2) via insulin/IGF Receptor or RTK 
stimulation. Activated AKT promotes MDM2 dependent p53 proteolysis and the 
phosphorylation of BAD which leads to the inhibition of apoptosis. AKT also suppresses 
apoptosis by activating the mTOR-RAPTOR kinase complex (mTORC1). The 
mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that regulates 
eukaryotic cell growth and metabolism by controlling fundamental cellular processes 
such as protein translation/synthesis, lipid synthesis, and autophagy. The mTOR kinase 
can function in two distinct complexes, mTORC1 and mTORC2. The mTORC1 complex 






mTORC2 complex is unresponsive to rapamycin and nutrients.  AKT indirectly activates 
mTORC1 by associating with TSC1 in the TSC1/TSC2 complex to inhibit the GTPase 
Rheb. The accumulation of Rheb-GTP activates mTORC1 by inhibiting FKBP38. 
mTORC1 then phosphorylates p70 S6 ribosomal kinase which has a role in cell 
proliferation and positively regulating protein synthesis by increasing mRNA translation 
and thereby increasing protein synthesis. (Figure 1)7    
PI3K is inactivated when PIP3 is hydrolyzed to PIP2 by PTEN, a lipid 
phosphatase and the enzymatic antagonist of PI3K. PTEN is inactive in many lung 
cancers.  However, loss of PTEN function does not universally correlate with enhanced 
PI3K signaling as the cellular changes in tumors in response to diminished PTEN 
function are very different from those seen with gain of PI3K and have different drug 
sensitivities.11 
Downstream Targets: The Importance of mTORC1  
  
Figure 2: Overview of the function of mTOR Inhibitors. Left panel: Untreated mTORC1 inhibits 
autophagy, and promotes growth and proliferation by activating S6K and inhibiting 4EBP. mTORC1 also 







prevent mTORC1 from inhibiting autophagy and promoting growth and proliferation via S6K activation. It 
also prevents inhibition of mTORC2 by mTORC1 allowing AKT activation. Growth and proliferation can 
still be promoted by mTORC1 by inhibition of 4EBP.  
  
mTORC1 promotes cell growth and proliferation by increasing anabolic processes 
like nucleotide, protein, and lipid synthesis and suppressing catabolic processes such as 
autophagy. One target of mTORC1 related to protein synthesis is p70 ribosomal protein 
S6 kinase (S6K). S6K is phosphorylated by mTORC1 on its hydrophobic motif. S6K can 
then be activated by PDK1 via a second phosphorylation on its T-loop. S6K then goes on 
to activate its substrates via phosphorylation to promote mRNA translation. The first 
identified substrate of S6K was a component of the 40S ribosome, ribosomal protein S6. 
(Figure 2)11 In addition, mTORC1 also promotes protein translation by phosphorylating 
eIF4e Binding Protein (4EBP) which normally inhibits the assembly of translational 
machinery by binding to eIF4e. Phosphorylation by mTORC1 changes the conformation 
of 4EBP, freeing eIF4e and allowing translation machinery to assemble. Both S6K1 and 
4EBP bind raptor, a critical mTOR-interacting scaffold protein, and are regulated by 
amino acid levels. Depletion of amino acids, especially the branched chain amino acids 
leucine and isoleucine, leads to reduced protein synthesis due to dephosphorylation of  
S6K1 and 4EBP. This is rapidly revered by replenishing amino acid levels.  In addition, 
S6K1 is also regulated by glycolysis, mitochondrial function, cell stress, and growth 






mTORC1 induced proliferation requires increased lipid synthesis to meet the 
membrane assembly needs of dividing cells. The S6K1 pathway is also involved in lipid 
synthesis by activating transcription factors called sterol response element binding 
proteins (SREBPs).11 
mTORC1 also plays an important role in promoting DNA replication by 
regulating nucleotide synthesis. Again, mTORC1 acts via S6K1 which activates 
carbamoyl-phosphate synthase, an enzyme involved in the de-novo pyrimidine synthesis 
pathway and urea cycle, via phosphorylation. mTORC1 activation of SREBPs also 
controls nucleotide synthesis. The activated SREBPs redirect more cellular resources to 
the pentose phosphate pathway generating more NADPH needed for lipid and nucleic 
biosynthesis.  mTORC1 also increases nucleotide synthesis by upregulating bifunctional 
methylenetetrahydrofolate dehydrogenase/cyclohydrolase which donates carbons for 
purine synthesis in the mitochondrial-tetrahydrofolate cycle.11  
Another important target of mTORC1 is hypoxia inducible factor 1 (HIF1), a 
transcription factor involved in the expression of survival genes. Translation of the alpha 
subunit of HIF1 is increased following mTORC1 activation leading to increased 
production of glycolytic enzymes. This marks a shift in glucose metabolism, leading to 
increased glycolysis and reduced oxidative phosphorylation. In addition, as discussed 
later, mTORC1 also promotes cell growth by inhibiting the key catabolic process of 
autophagy.11  






The PI3K/AKT/mTORC1 signaling pathway controls cell growth, proliferation 
and survival by increasing anabolism, and suppressing catabolism, including autophagy, 
which is discussed later.2 There are three classes of PI3K proteins with class IA having 
the strongest association with cancer.7 PIK3CA encodes for the catalytic subunit of PI3K, 
p110a. It is mutated in approximately 3-12.7% of NSCLCs.12 Studies of p110a inhibitors 
on leukemic cells have shown they inhibit growth, suggesting that PI3K is an 
oncoprotein. There are three common ‘hotspot’ mutations in PIK3CA that are commonly 
found in cancer; one in the kinase domain and two in the helical domain. All three 
mutations cause a gain of function of p110 and a significant upregulation of PI3K’s lipid 
kinase activity. This increased oncogenic activity of PI3K is observable by elevated 
phosphorylation of AKT which can be shown on a Western Blot. It can also be shown in 
cell culture by induced anchorage independent growth.10 
Overexpression of PI3K or its downstream effectors leads  to constitutive 
mTORC1 activation and is pivotal to many LSCCs as it increases protein translation, 
proliferation and inhibition of the autophagy pathway through repression of ULK1 (Unc-
51 Like Autophagy Activating Kinase 1)  and the MIT/TFE family of transcription 
factors. Similarly, tumor suppressors TP53 and LKB1 function as negative regulators of 
mTORC1. TP53 and LKB1 mutations are common in cancers, conferring increased 
mTORC1 activity. In addition, mTORC2 has also been implicated as an oncogene 
through activation of AKT causing increased glucose uptake, glycolysis, and inhibition of 






Cancer Therapeutics: mTORC1 inhibitors  
To investigate PI3K-mTOR signaling in cell lines, we used mTORC1 kinase 
inhibitor Everolimus (see Materials and Methods). However, clinically mTOR inhibitors 
have shown limited therapeutic efficacy when administered as single agents. One reason 
for this is the complexity of the PI3K/AKT/mTORC1 axis. When mTORC1 alone is 
inhibited, there is an activation of the mTORC1 negative feedback loop. This results in 
the activation of AKT by S6K induced upregulation of the IRS-1 and TGFBR-1 
pathways. Therefore, inhibition of mTORC1 alone is not sufficient to fully suppress 
PI3K-AKT signaling.13 Another reason for the lack of efficacy of mTORC1 inhibitors is 
that they do not equally inhibit the phosphorylation of all mTORC1 substrates equally. 
Thereby some substrates such as S6K1 are considered rapamycin sensitive while others 
such as 4EBPs are considered rapamycin insensitive. Interestingly, mTORC1 inhibitors 
also activate autophagy. The role of autophagy in cancer is complex and often context 
dependent--in some cases activation of autophagy promotes cancer survival while in 
other cases, usually earlier stages, it prevents tumorigenesis. The activation of autophagy 
by mTOR inhibitors have been shown to help cancer cells survive nutrient deprived 
conditions by increased recycling of cellular materials, allowing the cell to become 
resistant to apoptotic cell death. Though currently available mTORC1 inhibitors have 
limited clinical efficacy, there remains a strong interest in mTORC1 and downstream 






mTORC1-actitvated S6K1 phosphorylates and activates oestrogen receptor α leading to 
breast cancer progression.14  
Treatment of LSCC is most effective in patients with targetable oncogenes such 
as EGFR.2 One of the first lines of treatment in LSCC are EGFR TKIs. However, over 
activation of the PI3K/AKT/mTORC1 axis is a common resistance mechanism to EGFR 
TKIs accounting for 14.9% of resistance events. This is of great concern as co-occurrence 
of EGFR activating mutations with mutations in the PI3K pathway predicts a worse 
prognosis for LSCC patients. Because of this, despite the limited efficacy of mTORC1 
inhibitors including Everolimus, development of new inhibitors of the 
PI3K/AKT/mTORC1 axis still remains of great interest in the treatment of LSCC. 
Moreover, the Ras/Raf/MEK/ERK pathway inhibits the TSC1/TSC2 complex as ERK 
phosphorylates TSC2. This promotes Rheb-mediated activation of mTORC1 independent 
of the PI3K/AKT pathway. This complicates the potential use of PI3K/AKT/mTORC1 
inhibitors as potential therapeutics due to parallel survival signaling mediated by the Ras 
pathway. Application of PI3K inhibition sensitizers, such as CDK4/6 inhibition, may 
enhance clinical response.13,14 Recently, ATP-competitive catalytic inhibitors that inhibit 
both mTORC1 and mTORC2 have also shown promise.   
NRF2 and the Antioxidant Response  
Nuclear factor erythroid 2-related factor (NRF2) is a transcription factor encoded 
by NFE2L2 that is part of an evolutionary conserved intracellular defense mechanism to 






transcription factors and contains the highly conserved basic region-leucine zipper motif. 
NRF2 and its principle negative regulator, the E3 ligase adaptor Kelch-like ECH-
associated protein 1 (KEAP1), reduce oxidative stress through regulation of glutathione 
and thioredoxin dependent systems and are critical for the maintenance of redox, 
metabolic and protein homeostasis and regulation of inflammation.2  Reactive oxygen 
species (ROS) are generated in the body from external exposure or internally from 
metabolic processes. They include O2•−, H2O2, •OH, RO2•, RO•, 1O2, and O3 and are 
primarily produced by the mitochondria during aerobic respiration. Nearly all enzymes 
that utilize oxygen as a substrate are known to produce ROS.15 Oxidants can act as 
signaling molecules for cell division, immune function, and autophagy. ROS present a 
big concern for the lung because even though it is an internal tissue it is continuously 
exposed to the outside environment during respiration. For that reason oxidative stress is 
not only implicated in the initiation of lung cancer, but also asthma and COPD. 
Consequently, NRF2 is a potential therapeutic target for many respiratory diseases.16  
NRF2’s Role as a Transcription Factor  
Redox homeostasis is maintained through a counterbalance of ROS and 
antioxidant systems.15 NRF2 is a potent transcriptional activator that recognizes and 
binds to a unique DNA sequence called the antioxidant response element (ARE). By 
regulating expression of ARE-containing genes, NRF2 can prevent oxidative stress-
induced genetic damage by inducing antioxidant and radioprotective mechanisms and 






allowed to accumulate by inactivation of the KEAP1. sequestering mechanisms there is a 
swift activation of the ARE-dependent cytoprotective genes.3,15 Though ROS can cause 
damage to cells, recent studies have identified them as signaling molecules for many 
intracellular proteins. The NRF2 transcriptional response via the ARE-dependent genes 
reduces the levels of ROS below the threshold for these proteins. These proteins are often 
involved in tumorigenesis and include  NF-𝜅B, mitogen-activated kinases, PI3K, and 
hypoxia inducible factor 1.2  NRF2 has long been thought of as a ‘pro-survival’ 
transcription factor that protects us from a variety of diseases. However, despite NRF’s 
role in preventing tumorigenesis, NRF2’s protective abilities are often used by cancer 
cells to create a pro-survival microenvironment to foster tumor growth and drug 
resistance.15  







Figure 3: Transcriptional Targets of NRF2. NRF2 binds to antioxidant response elements to increase 
transcription of gene involved in glutathione production and regeneration, ROS and xenobiotic 
detoxification, the TXN-based antioxidant systems, NADPH regeneration, and heme and iron metabolism.  
 
NRF2 and its downstream targets regulate antioxidant signaling and cell survival. 
The role of NRF2’s downstream targets include antioxidants and detoxification enzymes 
but also expand to stress response genes, xenobiotic metabolizing genes, genes involved 
in the ubiquitin-mediated proteasomal degradation system, intracellular redox-regulating 
genes, genes controlling cell growth and genes encoding transporters. (Figure 3)17 The 
many functions of NRF2 can be explained by the various antioxidant response element 
(ARE)-regulated genes it controls and it is clear that the NRF2-dependent response is 
involved in a cell’s attempt to defend itself from harmful conditions.15 As mentioned 
earlier NRF2 maintains redox homeostasis through a counterbalance of ROS and 
antioxidant systems. It does this through many mechanisms including by inducing the 
synthesis of reducing factors such as the antioxidant Glutathione and NADPH.   
NRF2 also controls the basal and induced expression of a variety of drug 
metabolizing enzymes and has been linked to genes that play a role in drug resistance 
including transporters such as multidrug resistant associated protein 1-6. Initiation of 
drug metabolism through ARE likely developed as a strategy of detoxification of 
endogenous oxidants but evolved to include environmental toxins.18  
As discussed in the autophagy section below NRF2 also regulates some oxidant 






Regulation by KEAP1   
  
 
Figure 4: The NRF2/KEAP1 Pathway. Under constitutive conditions NRF2 is bound to KEAP1 and 
sequestered in the cytosol. Ultimately this complex is ubiquitinated and degraded by the proteasome. In the 
presence of ROS NRF2 is freed from KEAP1 and can travel to the nucleus where it promotes transcription 
of antioxidant proteins. Eventually these antioxidant proteins eliminate ROS species and NRF2 remains 
sequestered in the cytosol by KEAP1.  
Kelch-like ECH-associated protein (KEAP1) serves as an adaptor for the Cullin 3 
based ubiquitin E3 ligase for NRF2. NRF2 is targeted for ubiquitin-mediated degradation 
by KEAP1 until the cell encounters oxidative stress/ oxygen free radicals. KEAP1 is rich 
in thiols and contains many reactive cysteine residues. Consequently, oxidative stress 






in KEAP1. This inactivates KEAP1 and releases NRF2. NRF2 is then free to move to the 
nucleus, bind to the antioxidant response element (ARE) and enhance the production of 
antioxidants to eliminate the free radicals. (Figure 4)16  
Protein turnover is the major mechanism for NRF2 regulation as Keap1 is a 
ubiquitin ligase that marks NRF2 for degradation. This keeps the concentration of free 
NRF2 low and henceforth also keeps the expression of NRF2 target genes low. When 
exposed to oxidative stress the cysteine thiols of KEAP1 and NRF2 are modified, 
inhibiting the ubiquitination of NRF2 and altering NRF2/Keap1 complex. The KEAP1 is 
therefore trapped in the complex and newly synthesized NRF2 can bypass KEAP1 and 
enter the nucleus. The level of NRF2 is increased and ARE-mediated transcription is 
upregulated. When oxidant or toxin exposure has ceased, KEAP1 translocates to the 
nucleus during the post induction period and removes NRF2 from the ARE regulatory 
sequences. NRF2 is shuttled back to the cytoplasm where it is degraded to turn off the 
NRF2-dependent response.15  
NRF2 and Cancer   
Mutations in the NRF2/KEAP1 stress response pathway are major drivers of 
cancer and are found in approximately 33% of  LSCC according to the Cancer Genome 
Atlas.19 Cancers with elevated NRF2 levels are associated with reduced survival due to 
chemoresistance and high proliferation.2 However, NRF2 has a complex role in lung 
cancer as it acts as both a tumor suppressor and an oncogene. Its role as a TSG relates to 






cancer metastasis.16 Loss of NFE2L2 in coordination with other common mutations has 
been shown to lead to early tumor growth, indicating oxidative stress as a driver for the 
beginning stages of tumorigenesis. However, in transgenic mouse models loss of 
NFE2L2 is also associated with increased survival by promoting oncocytomas. Relatedly, 
in lung diseases such as emphysema and COPD NRF2 deficiency or downregulation is 
linked to disease etiology.16,20 Despite NRF2's role in clearing ROS, mutations such as 
T80K in the ETGE motif of the Neh2 domain interrupt KEAP1-NRF2 binding and lead 
to constitutively active NRF2 have been found in many pre-malignant LSCC lesions. 
High nuclear levels of NRF2 seem to promote cancer cell proliferation by creating an 
environment conducive to growth and survival despite detrimental conditions.21,22 While 
reduced NRF2 levels can also cause cancer because of the lack of protection from 
carcinogens, elevated NRF2 levels can cause anabolic pathways to become activated and 
stimulate cell proliferation leading to cancer cell transformation.  This thesis will focus 
on the oncogenic role of NRF2 but it’s important to recognize the dual role of NRF2 as a 
tumor suppressor.2 Furthermore, in some cancer cells the antioxidant abilities of NRF2 
are hijacked to increase resistance to oxidants in cancer therapeutics such as cisplatin, 
doxorubicin and etoposide, creating chemoresistant tumors. In mice with KRAS-induced 
lung tumors drug sensitivity can be imparted to chemoresistant cancer cells with the use 
of the NRF2 inhibitor brusatol.22  In addition, research by Wang & Sun showed that both 
introduction of NRF2-small interfering RNAs and overexpression of KEAP1 using 






inhibitors of NRF2 that have been explored as therapeutic agents are agonists of the 
glucocorticoid receptor such as dexamethasone. Following ligand mediated activation 
and binding to the glucocorticoid response element, dexamethasone has been shown to 
inhibit transcriptional activity of NRF2.3  
Also of note, loss of function mutations in KEAP1 also have a similar effect to 
NRF2 activating mutations as they keep NRF2 constitutively active and are common in 
cancers including LSCC where environmental factors are important etiological 
components.16 In LSCC loss of heterozygosity at the genomic location of KEAP1, 
19p13.2, is common. In addition, mutations in the Kelch and linker domains of KEAP1 
that prevent NRF2 binding are also common. It is suggested that NRF2 inhibition during 
chemotherapy may be more effective when KEAP1 is non-functional or under 
expressed.15 However, it unclear whether single mutations in either KEAP1 or NFE2L2 
can initiate malignant transformation. Initiation and progression of malignant 
transformation requires cooperativity between two or more oncogenic driver mutations. 
For example, experiments done by Best & Souza showed that mice with elevated NRF2 
due to a knockdown of Keap1 do not spontaneously develop tumors. However 
simultaneous deletion of KEAP1 and PTEN, a negative regulator of PI3K, promotes 
adenocarcinoma formation in the murine lung.2 Co-occurrence of NRF2 mutations with 
alterations in the PI3K pathway have the strongest association with malignant 






Overall elucidating the mechanism through which NRF2 modulates the 
progression of pulmonary diseases is important for the development of therapeutics to 
target this pathway. Interestingly, NRF2 deletion in NSCLC cells has been shown to 
completely suppress tumor formation in athymic mice suggesting that NRF2 inhibitors or 
CRISPR-Cas9 NRF2 genes editing could be used to treat NSCLC. Discovery of NRF2 
targeted agents could be a game changer not only for lung cancer but a variety of 
respiratory diseases.16  
Autophagy  
Overview:  
Autophagy is a highly evolutionary conserved process that promotes recycling of 
macromolecules in response to a variety of cellular stresses such as nutrient deprivation, 
hypoxia, abnormal protein aggregation, and organelle damage. It serves a role in cell 
death and tumor suppression as well as maintaining metabolism and homeostasis. There 
are three major types of autophagy: macroautophagy (the focus of this thesis), 
microautophagy and chaperone-mediated autophagy. When cells are deprived of 
nutrients, autophagy is upregulated to maintain a source of proteins and nutrients 
essential to energy production. It also plays a housekeeping role to prevent cellular 
damage and serves to clear damaged organelles, including the mitochondria and 
peroxisomes, removes misfolded proteins, eliminates intracellular pathogens and 
maintains genomic integrity.23 An important mechanism of autophagy is the intracellular 






organelle. The autophagosome expands by engulfing intracellular cargo and then reaches 
maturity when it fuses with the lysosome and becomes the autolysosome. (Figure 5)14 
The autolysosomal contents are then degraded by lysosomal proteases and exported back 
into the cytoplasm for re-use for energy or anabolism of macromolecules.14  
Autophagy’s role in cancer is complex and context dependent-- In mouse models 
of NSCLC autophagy ablation can initiate early tumor growth. However, in later stages, 
loss of autophagy dampens tumor growth. The heterozygous loss of the autophagy gene 
Becn1 in mice causes tumorigenesis and deletion of Atg5 or Atg7 leads to the 
development of hepatomas. These findings suggest that autophagy plays a role in tumor 
suppression. On the other hand, in some cases autophagy is localized to the hypoxic and 
metabolically stressed areas of the tumor, enabling tumor cell survival. Conversely, the 
absence of autophagy may inhibit tumor growth due to the accumulation of defective 
mitochondria and reduced cellular respiration, which can impair cell survival and cause 
diminished stress tolerance. Tumors that are dependent on autophagy are labelled 
“autophagy-addicted” and autophagy inhibitors are of particular interest for treatment of 
these tumors.20,24  
Both oncogenes, PIK3CA and NFE2L2, investigated in this thesis play a role in 
the autophagy pathway as elaborated on below. My central hypothesis is that PIK3CA 






of the autophagy pathway.  
 
Figure 5: Signaling Pathways Regulating Autophagy. Autophagy is a multistep self-degradative process 
with several key steps: (a) the phagophore is formed from the ER membrane. Its formation is controlled by 
Beclin-1 in response to stress. (b) At the phagophore ATG5 and ATG12 conjugate. (c) LC3 is processed 
and inserted into the membrane of the extending phagophore. (d) Selective targets are captured for 
degradation. (e) The autophagosome fuses with a lysosome to form an autolysosome.  
 
Assays to Study Autophagy   
Accumulation of select autophagy-related proteins can be measured by Western 






below. When autophagy is inhibited these proteins are unable to be broken down and 
they therefore accumulate within the cell. Methods to detect levels of these proteins can 
be used to measure autophagy inhibition.   
LC3  
There are two types of macroautophagy, selective and non-selective. Selective 
autophagy relies on adaptor proteins to identify contents to be degraded. Microtubule 
protein light chain 3 (LC3-II) is a cytosolic adaptor protein that is cleaved and then 
recruited and integrated into the growing autophagosome on both the internal and 
external surfaces. LC3 integration is dependent on the ATG5-ATG12 complex. LC3-II is 
a good indicator of autophagy inside cells. When autophagy is active LC3-II synthesis 
and processing is increased but it is degraded in the autolysosome making detectable 
levels of LC3-II very low. When autophagy is inhibited LC3-II remains undegraded and 
accumulates to high levels inside the cell.14  
p62/ sequestosome 1   
p62 is a multifunctional adaptor protein that interacts with LC3-II on the 
autolysosome. Like LC3-II it is also degraded within the autolysosome when autophagy 
is active and accumulates when autophagy is inactive. p62 facilitates selective autophagy 
by binding ubiquitinated protein aggregates and delivering them to the autophagosome. 
NF-κB signalling is also regulated by p62, with elevated p62 levels inducing 
tumorigenesis by deregulating NF-κB signaling. As discussed below, p62 plays a role in 







An initial step in the autophagy pathway is the conjugation of ATG5 with 
ATG12. ATG16 complexes with ATG5-ATG12 to promote expansion of the nascent 
phagophore. Recruitment of LC3 is dependent on the presence of ATG5-ATG12 on the 
phagophore membrane. However, once the phagophore is completely formed ATG5-
ATG12 dissociates.   
ATG7  
Atg7 is involved in the initiation of autophagosome synthesis. It is an E1 
ubiquitin-activating enzyme that serves in the elongation step of the phagophore by 
activating ATG12 and LC3-I mediated conjugation systems.25  
Regulation of Autophagy by the PI3K/mTOR Pathway  
The autophagic mechanism is regulated by signaling pathways involving 
coordination of many proteins, including mTORC1 and mTORC2, which are involved in 
nutrient sensing and regulation of cell growth. When nutrients are plentiful mTOR 
inhibits autophagy and promotes cell growth by inducing ribosomal protein expression. 
As discussed earlier the PI3K protein and its corresponding gene PIK3CA are 
investigated throughout the laboratory work of this thesis. mTORC1 is activated 
downstream of PI3K. Therefore upregulation or downregulation of PI3K will have a 
corresponding effect on mTORC1 and on autophagy. Autophagy is initiated by AMP 
dependent kinase (AMPK) activation of ULK, a serine/threonine kinase.  Activated 






autophagy as phosphorylated ULK1 cannot be activated by AMPK, thereby inhibiting the 
ATG1/ULK-1/-2 complex at the early stage of phagophore formation from the lipid 
bilayer. mTORC1 can also be negatively regulated by AMP-activated protein kinase 
(AMPK). When mTORC1 is suppressed, as is the case in the event of hypoxia or low 
cytosolic ATP levels, there is an increase in AMP which induces autophagy by activating 
AMPK.14 The MiT/TFE family of transcription factors promote expression of genes 
needed for autophagy. The regulation of the MiT/TFE family of transcription factors is 
another mechanism by which mTORC1 suppresses autophagy. By phosphorylating 
TFEB, a member of the MiT/TFE family, and preventing its translocation to the nucleus 
and mTORC1 prevents expression of lysosomal hydrolases needed for formation of the 
autolysosome.     
In cancer cells, autophagy inhibits cancer cell survival and facilitates cell death 
thereby promoting tumorigenesis. The mTOR complex is a major target for current and 
potential cancer therapeutics. As mentioned earlier, reduced mTOR activity induces 
autophagy and causes increased catabolism and reduced cell growth. Therefore 
rapamycin, which targets mTOR and reduces its activity, is used in cancer therapy as it 
blocks protein translation, inhibiting cell growth and also promotes autophagy.14 In lung 
cancers, the autophagy pathway’s role in protecting cells from environmental toxins is of 
particular interest as the bronchial epithelial cells are in direct contact with the outside 
world via the air inhaled. In addition, mitophagy, the autophagy-dependent degradation 






of carcinogenic ROS.23 The interruption of the autophagy pathway could be a key initial 
step that makes HBEC more susceptible to mutations caused by environmental toxins 
such as those found in cigarette smoke or pollutants and ultimately lead to the 
progression into lung cancer.14  
NRF2 and autophagy   
 
Figure 6: Schematic representation of the positive feedback loop between p62, NRF2, in autophagy. 
The presence of ROS from damaged proteins and organelles free NRF2 from being sequestered in the 
cytoplasm by KEAP1. This allows NRF2 to travel to the nucleus and promote the transcription of p62. 
After translation p62 binds to KEAP1 and prevents it from sequestering NRF2.  
A key link between NRF2 and the autophagy pathway is the selective autophagic 
cargo receptor protein, p62. p62 removes KEAP1 suppression of NRF2 even in the 
absence of electrophiles leading to activation of NRF2 and increased ARE-dependent 






Therefore accumulation of NRF2 leads to increased p62 expression. (Figure 5)18  In 
addition, p62 also positively regulates NRF2 transcription creating a positive feedback 
loop and when the autophagy pathway is inactivated there is a large accumulation of p62 
levels leading to increased levels of NRF2.26,27 This is supported by the experiments of 
Komatsu that found an overexpression of NRF2 in autophagy defective mice.28 KEAP1 
binds to the KEAP1-interacting region domain on p62 which is similar to the KEAP1-
interacting ETGE motif on the Neh2 domain of NRF2 allowing p62 to sequester KEAP1 
in the autophagosome. Thus, p62 plays a crucial role in regulating KEAP1 turnover and it 
has been shown that elevated levels of p62 reduces the half life of KEAP1. Without the 
presence of KEAP1 in the cytosol, ubiquitination of NRF2 is impaired and NRF2 
becomes active. This is considered the non-canonical activation pathway for NRF2 since 
it does not require ROS.  While our experiment models NRF2 as an oncogene by 
inducing its overexpression, impaired formation of the autophagosome via ATG7 or p62 
deficiencies may be a contributing factor to the high NRF2 levels that lead to 
tumorigenesis instead of mutations in NFE2L2 or KEAP1.25 
Much is still not known about p62 regulation of KEAP1. Some studies have 
suggested that p62 has increased affinity for KEAP1 when it is phosphorylated resulting 
in prolonged accumulation of NRF2 and transcriptional upregulation of its target genes. 
In addition, ULK-1 is  also thought to interact with p62 and facilitate its phosphorylation 
leading to increased degradation of cargo proteins including KEAP1 and thereby 






downstream target of PI3K prevents the ATG1/ULK-1/-2 complex formation at the early 
stage of phagophore formation releasing ULK-1 to associate with and phosphorylate p62, 
leading to NRF2 protein stabilization. By this mechanism PI3K indirectly leads to 
increased levels of NRF2.25  
The role LC3 plays in the link between the NRF2 pathway and autophagy is not 
completely understood. The KEAP1-interacting region domain and the LC3-interacting 
region domain are very close to each other on p62. Some studies have suggested this 
adjacency leads to competitive bind, therefore limiting the KEAP1 sequestering 
capabilities of p62. However, other studies suggest that the formation of the KEAP1-p62-
LC3 complex are necessary for the clearance of ubiquitin aggregates in response to 
oxidative stress.25  
Recent studies of autophagy deficient mice have shown prolonged NRF2 
activation leads to cancer. When autophagy is ablated by deletion of genes encoding for 
critical autophagy proteins, p62-KEAP1 aggregates accumulate in the cytosol resulting in 
prolonged NRF2 activation. ATG7 deficient mice provide an important model for the 
connection between NRF2 and autophagy. When ATG7 is deleted in mouse models, 
phagophore elongation is blocked leading to impaired formation of the autophagosome. 
KEAP1-p62 accumulation and constitutive NRF2 activation were observed in ATG7-
deficient mice.25 Similarly, these same KEAP1-p62 aggregates with NRF2 pathway 
activation were found in human hepatocellular carcinomas with ATG7 deficiencies. 






produced and the NRF2 pathway was blocked. In addition, anchorage independent 
growth was also suppressed in the absence of p62.22 Much is still not known about the 
role of the interplay between the NRF2 and PI3K/mTOR-autophagy pathways in cancer 
initiation and progression. Reciprocal control of NRF2 and autophagy may be context 
dependent and a comprehensive understanding of the mechanism is needed before further 









The cell lines were plated at a density of 100cells/mL in a six well plate. Two 
wells were left as controls and only contained media. The cells were allowed to grow for 
6 days in the incubator at 37°C and 5% CO2. They were then fixed with 10% buffered 
formalin, stained with 0.5% Crystal Violet Dye, and air dried overnight. The 6-well plate 
was then imaged with Bio-Rad Molecular Imager ChemiDoc™ XRS+ with Image Lab™ 
Software.  
Initial Cell Lines 
Frozen aliquots of HBEC3-KT cells transfected with the genes HcRed, E545K 
mutant PIK3CA, and T80K mutant NFE2L2 were thawed and plated. HBEC3-KT are a 
line of cells manufactured by American Type Culture Collection (ATCC) that are non-
tumorigenic and immortalized by the introduction of CDK4 and hTERT.29,30 The 
transfected cell lines were allowed to grow to confluence in an incubator at 37°C and 5% 
CO2.  Airway Epithelial Basal media manufactured by the American Type Culture 
Collection (ATCC) was used to house the cell lines. It was supplemented with the 
Bronchial Epithelial Cell Growth Kit (also manufactured by ATCC) and 1X Penstrep.  
Lentiviral Transduction 
The HBEC-NFE2L2 line was plated in a 6-well dish. Lentiviruses diluted at a 
1:1000 containing HcRED or PIK3CA were transduced using spin infection at 1,200 x g 






to help the virus bind to the plasma membrane more efficiently. This process created our 
HBEC- NFE2L2 + HcRED and HBEC-NFE2L2 + PIK3CA cell lines which we expanded 
into 100mm dishes. Later, we repeated this process with Lentiviruses containing an LC3 
fusion protein with dual fluorescence of mCherry and GFP with the four parental cell 
lines in a six well plate. This lentivirus also contained a puromycin resistance gene which 
allowed us to select for the transfected cells by adding puromycin at a 1:500 
concentration to each well.  
Drug Dilution with Everolimus and Nutrient Deprivation 
The four cell lines were plated at a density of 50,000 cells/mL in 96 well plates 
and allowed to grow to confluence. Once they reached confluence, Everolimus, a 
mTORC1 inhibitor, was added in concentrations varying from 0.125mM to 1mM. The 
drug concentrations were obtained using serial dilutions in DMSO and RPMI + 
Glutamax™ (1X) serum free media manufactured by Gibco.  Three wells per cell line 
served as a control and were treated with only DMSO in serum free media. The cells 
were then incubated for 48 hours.  
Nutrient deprivation was also performed on these 96 well plates. The media was 
aspirated off wells and 100µL of minimal media, Earle’s Balanced Salt Solution 
manufactured by Gibco, was added. 6 wells per cell line were kept as a control. The cells 
were then incubated for 1 hour.  
The drug treated, nutrient deprived, and control wells were then fixed and stained 






incubated for another hour. They were then placed in the fridge until they were imaged 
by the BioRad cytation imaging reader.  
Live Cell Imaging with Everolimus and Chloroquine 
Each cell line was plated at a density of 65,000 cells/mL into three wells of a 
twelve well plate. The cells were incubated at 37°C and 5% CO2 for 48 hours. The cell 
lines were treated with 100µL of 10mM Everolimus, 50mM chloroquine, or DMSO 
diluted in RPMI in each of the three wells. The plate was then placed in the BioRad 
cytation imaging reader with a 10X objective lens at the same incubation settings. Nine 
fields per well were selected and images were taken at the initiation of the experiment 
and then at a time point of one hour for 18 hours using laser autofocusing. Light-emitting 
diode filter cubes were used to image GFP and mCherry fluorescence. Using Gen5 
imaging software, the green and red LC3 puncta were quantitated by setting fluorescence 
intensity thresholds to count green/red puncta and red puncta alone.31 
Western Blots for NRF2, PI3K, Downstream Targets and Autophagy Markers 
Cells were plated in 100mm plates and allowed to grow to confluence. After 
splitting cells for maintenance, 900 µL of the 1mL cell suspension was pelleted. Cells 
were lysed with 100µL of 8M Urea Lysis Buffer and then sonicated at 20% amplitude for 
15 seconds. The Pierce BCA protein Assay by ThermoFischer Scientific was used to 
normalize the samples. The normalized samples were boiled with SDS for 6 minutes then 
loaded into either 12% Poly-Acrylamide Gel or a Mini-Protean™ pre-cast gel by 






SDS-PAGE at 100V for 1 hour and the proteins were transferred to a polyvinylidene 
(PVDF) membrane by running the gel and membrane at 100V for 1 hour.  
The membrane was blocked in TBS-T-BSA for 30 minutes. The primary 
antibodies were then added at the appropriate dilutions and the membrane was incubated 
overnight. The primary antibodies used were: NRF2 (Cell signaling), NRF2 (Santa Cruz 
Biotechnologies), PI3K (4294), PI3K (4253), AKT, phospho-AKT, ATG6, LC3, p62, 
GAPDH.  GAPDH was used as a loading control. GAPDH is a housekeeping gene that is 
highly and constitutively expressed in many cells and tissues. The following day the 
secondary antibody diluted 1:5000 in TBS-T-BSA blocking solution was added and the 
membrane was incubated for 1 hour. The secondary antibodies were either anti-mouse or 
anti-rabbit HRP-conjugated antibodies depending on the primary antibody used. An 
enhanced chemiluminescent mixture was added and the membrane was imaged using the 
Bio-Rad Molecular Imager ChemiDoc™ XRS+ with Image Lab™ Software.  
Western Blots for Everolimus treated Cells 
This Western blot procedure was repeated with Everolimus treated cell lines. The 
cell lines were plated in two six-well plates at a density of 25,000 cells/mL and allowed 
to grow to confluence in an incubator at 37°C and 5% CO2. Everolimus at concentrations 
of both 1mM or 2mM was then added to each cell line. DMSO was also added to each 
cell line to establish controls.  
Three samples per cell line, DMSO treated (control), 1mM Everolimus treated, 






was run according to the procedure above. Primary antibodies for LC3, p62, pS6, total 





Table 1: Co-occurrence of Commonly Mutated Genes in LSCC. Using cBioPortal 469 patient samples 
from the Pan-Cancer Atlas were queried for co-occurrence of six commonly mutated genes in benign 
premalignant LSCC lesions: FAT1, EP300, NFE2L2, NOTCH1, PIK3CA, and TP53.   
 
 The general aim of our research was to investigate which genes are mutated in 






commonly mutated genes in benign premalignant  LSCC lesions were investigated. These 
genes, FAT1, EP300, NFE2L2, NOTCH1, PIK3CA, and TP53, when mutated are all 
considered “first hits”. Mutations of these genes are not sufficient to cause tumorigenesis 
on their own. Our research seeks to answer if two of these common mutations are 
combined in HBECs, is the “second hit” enough to initiate increased cell proliferation, 
attachment independent growth, inhibition of autophagy, and other hallmarks of 
tumorigenesis?  Using the computational bioinformatics web site, cBioPortal, we 
discovered which of the fifteen pairs of genes co-occurred in human LSCC by querying a 
data set of 469 patient samples from the Pan-Cancer Atlas (TCGA). The TCGA is the 
product of a collaboration between the National Cancer Institute and the National Human 
Genome Research Institute. By analyzing over 11,000 tumors from common types of 
cancer the TCGA seeks to further explain the molecular etiology of tumor formation. As 
shown in Table 1, of the 15 pairs of genes we queried, only two gene pairs displayed 
statistically significant co-occurrence, as defined by a Fisher exact test with p-value ≤ 
0.0532 (NFE2L2/PIK3CA and PIK3CA/TP53). We chose to follow up on 
PI3KCA/NFE2L2 mutations because both are oncogenic and have been implicated in the 
control of the autophagy pathway. Out of the samples queried, 88% of the NFE2L2 
mutations and 89% of the PIK3CA mutations are activating. The remainder are unknown 
but are predicted to also be activating.32 As discussed earlier autophagy has been shown 
to play a tumor suppressive role at the premalignant stages of tumorigenesis. When 






may accumulate leading to initiation of tumor growth. The nature of autophagy in cancer 
is bipolar and in later stages of tumor growth autophagy is often upregulated past basal 
levels to promote cell proliferation and the epithelial-mesenchymal transition. Our 
research focuses on determining how NFE2L2  and PIK3CA mutations interact to inhibit 
autophagy,  which will shed light on mechanisms by which these oncogenes promote 
tumor initiation.33 In addition,  abnormalities in tumor suppressor genes are not yet 
clinically applicable in treatment of LSCC and we sought to keep our research clinically 
relevant, we decided to focus on oncogenes only.2 This eliminated TP53-PIK3CA from 
consideration for our research.  
 To test the effect of the co-occurrence of PIK3CA and NFE2L2 we transduced a 
constitutively active PIK3CA (E545K) mutant gene into a cell line previously transduced 
with a constitutively active mutant form of NFE2L2 (T80K). The oncogenic variants of 
these genes we used for transduction are the same as those found in the TCGA database.  
In addition, HcRED was also transfected into the NFE2L2 cell line as a positive control. 
An HBEC line containing just HcRED was used as the negative control. Another cell line 
containing PIK3CA alone was used to compare the effects of PIK3CA alone with the 
effects of PIK3CA + NFE2L2. Proteins from all four cell lines were harvested for 
Western blot analysis. A figure comparing the concentration of various proteins between 









Figure 7: Western Blot analysis showing indicated protein levels following transduction of HcRED 
and PIK3CA lentiviral vectors into existing HBEC-NFE2L2 cell lines. This Western blot shows the 
difference in protein levels between the four cell lines for the protein products of the genes being 
investigated (NRF2 and PI3K) as well as AKT, a downstream target of PI3K. Two antibodies with different 
molecular weights for NRF2 were used.  
 To begin to investigate the possible cooperation between oncogenic NFE2L2 and 
PIK3CA mutations suggested by the results in Table 1, we performed a preliminary 
Western Blot to in order to compare protein levels between the four cell lines. The 
protein products, NRF2 and PI3K, of the genes being investigated were probed for to see 
if their expression increased in the presence of the second oncogene. In addition, AKT 
and P-AKT were also probed for. AKT is a downstream target of PI3K. When PI3K is 






AKT we sought to answer whether the mutant NFE2L2 gene would augment phospho-
AKT levels in the dual mutant.  
Two NRF2 antibodies were used: one high molecular weight made by Cell 
Signaling (CS) and one low molecular weight made by Santa Cruz Biotechnology (SC). 
The high molecular weight NRF2 antibody showed the presence of basal NRF2 
expression in the HBEC-HcRED and HBEC-PIK3CA lines. Both antibodies showed 
increased expression of NRF2 in the NFE2L2 transduced lines. The high molecular 
weight NRF2 antibody showed slightly increased expression of NRF2 in the HBEC-
NFE2L2+PIK3CA. Probing with the PI3K antibody showed elevated levels of PI3K 
expression in the HBEC-PIK3CA and HBEC-NFE2L2+PIK3CA above the basal PI3K 
expression shown in HBEC-HcRED. Equal amounts of total AKT, which includes both 
the phosphorylated and non-phosphorylated forms of AKT, were found in each cell line. 
The GAPDH antibody was used as a loading control and showed that the total protein in 
each sample loaded into the gel was relatively equal. (Figure 7) 
This experiment confirmed that the oncogenic NFE2L2 and PIK3CA cooperate. 
However, it does not answer how they cooperate. We hypothesized that one way they 
might cooperate is through the process of autophagy. In the Western Blot below in Figure 
8 we investigated the cooperation of NFE2L2 and PIK3CA on reducing autophagy by 







Figure 8: Western Blot Analysis of Autophagy Markers. Western blots showing the protein levels in 
each cell line for autophagy pathway components: ATG5, LC3, and p62. As these proteins are degraded in 
the autolysosome when autophagy is activated, higher levels of these proteins indicates inhibition of 
autophagy. 
Autophagy is one known cellular process that both the PI3K/AKT/mTORC1 and 
NRF2/KEAP1 signaling pathways are known to converge on. Reduction in autophagy is 
thought to be a key step for the malignant transformation of pre-cancerous LSCC lesions. 
We performed this second western blot to investigate if autophagy may be a process in 
which NRF2 and PI3K act synergistically to inhibit autophagy and push pre-cancerous 
LSCC to metastasis. Three key markers of autophagy were probed for: LC3, p62, and 






contents of the autolysosome, keeping their concentration at a relatively low level. When 
autophagy is inhibited these markers accumulate to high levels in cells.  
The highest levels of ATG5 and LC3 were found in the HBEC-NFE2L2-PIK3CA 
dual mutant. Levels of ATG5 were approximately equal in the HBEC-HcRED and 
HBEC-PIK3CA samples but elevated from basal levels in HBEC-NFE2L2-HcRED 
samples . Levels of LC3 were similar between HBEC-HcRED,  HBEC-PIK3CA, and 
HBEC-NFE2L2-HcRED samples. Levels of p62 were highest in the HBEC-PIK3CA 
sample. Compared to basal p62 expression levels as shown by the HBEC-HcRED, p62 
expression was elevated above basal levels in the HBEC-NFE2L2-PIK3CA sample but 
was below basal levels in the HBEC-NFE2L2-HcRED sample. GAPDH was used as a 





Figure 9: Western Blot Analysis of Cell Lines Treated with Everolimus. Blue text: Western Blot 
analysis of the effects of mTORC1 inhibition on expression levels of downstream mTORC1 targets across 
the four cell lines. Red text: Western Blot analysis of the effects of mTORC1 inhibition on select 
autophagy pathway components.  
Autophagy is controlled my mTOR. After we observed a significant reduction of 
autophagy in the dual mutant HBEC line in Figure 8, we wanted to know if the 
cooperation in reducing autophagy between oncogenic NFE2L2 and PIK3CA mutants 
could be reversed. To test this we treated the cells with the mTORC1 inhibitor, 
Everolimus. Samples were harvested for a Western Blot 48 hours post treatment. If the 






complete restoration of autophagy in the dual mutant HBEC line, despite mTORC1 
inhibitors being only know to interrupt constitutive PI3K activation and not NRF2 
activation. In order to compare mTOR regulation across the four cell lines we needed to 
first confirm mTORC1 inhibition by establishing controls. To verify mTORC1 inhibition 
by Everolimus, antibodies for total and P-S6K and antibodies for the total and 
phosphorylated form of P-S6K’s main substrate S6, a component of the 40S ribosome, 
were used. S6K is a major target of mTORC1 and therefore levels of P-S6K are a key 
indicator of mTORC1 activity. In addition, rapamycin, another mTORC1 inhibitor, has 
been shown to inhibit mitogen induced activation of S6K by preventing phosphorylation 
of Thr389 on S6K. Both Rapamycin and Everolimus inhibit the raptor scaffold protein, 
the binding site of S6K to the mTOR complex. This prevents mTORC1 from binding 
substrates such as S6K and mediating phosphorylation of rapamycin-sensitive sites. The 
mTORC1-S6K axis plays an important role in ribosome biogenesis, adipocyte 
differentiation, GSK3 regulation, and cell survival & motility.34 
 For each sample levels of phosphorylated S6 (P-S6) protein were highest in the 
control samples not treated with Everolimus. Levels of P-S6 were all elevated from the 
baseline established by HBEC-HcRED in the control, 1mM and 2mM Everolimus treated 
samples for the PIK3CA, NFE2L2, and dual mutant cell lines. For the PIK3CA and dual 
mutant line the samples showed a clear dose dependency as the 2mM Everolimus treated 
cells had reduced P-S6 expression compared to the 1mM treated cells.  Total S6 protein 






equally loaded and contained equal amounts of S6 protein. Phosphorylated S6 Kinase (P-
S6K) levels were highest in the dual mutant cell line and elevated from the baseline 
shown in HcRED in the PIK3CA and NFE2L2 transfected lines. In each cell line P-S6K 
expression was only observed in the control samples and not in the samples treated with 
Everolimus suggesting that Everolimus at both 1mM and 2mM concentrations is 
sufficient to prevent phosphorylation of S6K. Probing for total S6K showed that the 
observed reduced P-S6K levels are due to the inability of mTORC1 to phosphorylate 
S6K and not lack of S6K protein as the levels in each sample are comparable. (Figure 9). 
With these results we confirmed Everolimus was an effective mTORC1 inhibitor in our 
HBEC lines. This allowed us to proceed to investigating the effects of Everolimus 
treatment on autophagy activation in the dual mutant by probing for LC3 and p62.  
 LC3 levels were low in the HcRED line and equal between the control, 1mM, and 
2mM Everolimus treated line.  The PIK3CA transfected cells exhibited increased LC3 
levels in the control sample from baseline and also exhibited reduced expression in 
samples treated with Everolimus. However there does not appear to be a dose 
dependency as there is not a difference in expression in the PIK3CA line between the 
1mM and 2mM Everolimus treated samples. Both the NFE2L2 and dual mutant line had 
high LC3 expression in their control samples. Levels in the NFE2L2 line did not exhibit a 
response to Everolimus as the LC3 level shown on the Western Blot was similar between 






response to Everolimus with the greatest reduction in LC3 expression in the 2mM treated 
line.  
 
 The PIK3CA, NFE2L2, and the dual mutant showed an increase in p62 levels 
compared to baseline in the control sample. In the PIK3CA transfected line reduced p62 
levels are seen in the sample treated with 2mM Everolimus but not the sample treated 
with 1mM Everolimus. The NFE2L2 transfected line showed equal p62 levels across the 
three samples. The dual mutant showed decreased levels of p62 following treatment with 
Everolimus but the level of p62 detected was equal between the 1mM and the 2mM 
Everolimus treated samples indicating that the response in this line is not dose dependent. 
Probing with GAPDH indicated the protein levels across all twelve samples were 
comparable. (Figure 9)  
 An increased in LC3 and p62 protein levels indicates an inhibition of autophagy 
at the stage of autophagosome-to-autolysosome maturation because both proteins are 
degraded in the autolysosome. The reduction of p62 and LC3 levels following treatment 
with Everolimus observed in Figure 9 indicates the restoration of the autophagy pathway.  







Figure 10: Normalized Cell Count vs. Concentration of Everolimus. IC50 of Everolimus is shown 
showing the differing sensitivities of each cell line to mTORC1 inhibition.  
 
 In addition to measuring the effects of Everolimus on levels of key autophagy 
proteins using Western Blots, we also calculated the half maximal inhibitory content, 
IC50, of Everolimus for each cell line. IC50 indicates how much of a drug inhibitor is 
needed to reduce the targeted biological function by 50%. Therefore lower the IC50 
confers greater sensitivity to a drug. It is important to investigate whether Everolimus had 
the greatest effect on the dual mutant HBEC line. This would support our hypothesis of 
cooperation between the oncogenic NFE2L2 and PIK3CA mutations as well as have 







As hypothesized, Everolimus had the biggest effect as shown by the lowest IC50, 
on the HBEC-NFE2L2-PIK3CA line. Extrapolation from our results showed the IC50 of 
Everolimus for the HBEC-NFE2L2-PIK3CA line to be 0.46 µM. However these results 
are ambiguous as there is no intersection point for 50% as this cell line displayed 
maximal inhibition at 0.625µM, the lowest drug concentration we investigated. The IC50 
for HBEC-NFE2L2-HcRED was extrapolated to be 5.21 µM but these results were also 
ambiguous. The IC50 for HBEC-HcRED and HBEC-PIK3CA were 6.77 µM and 6.07µM 








Figure 11: Fluorescent Assay for Autophagy. Panel A: Schematic representation of the indications of 
fluorescent colors. The engineered mCherry-GFP-LC3 appears yellow before fusion of the autophagosome 
and lysosome as the red and green fluorescence mix. After fusion GFP is degraded due to the high acidity 
of the autolysosome and only red fluorescence is detected.  Panel B: Representative data of Fluorescent 
assay for HBEC cells expressing GFP mCherry. HBEC-HcRED cells were treated at indicated agents at 
indicated time points.  
 
To assay autophagy, we transduced an engineered form of LC3 into the cell lines. 
The LC3 fusion protein we used contains both GFP and mCherry. Fluorescence from 
GFP and mCherry are able to be read using the BioRad cytation imaging reader. Since 
the fluorescence from GFP is quenched under acidic conditions, when only red 
fluorescence from mCherry is present it indicates the presence of an autolysosome and 
the activation of autophagy. (Figure 11A)31  On the other hand, the presence of yellow 
fluorescence, the mixture of green and red fluorescent signals, indicates the 
autophagosome has not fused with the lysosome. Accumulation of the yellow fluorescent 
signal suggests there is a block in autophagy.35 
As in previous experiments we then treated the cells with Everolimus and the 
control (DMSO). In addition, we also treated with chloroquine. Chloroquine is an 
autophagy inhibitor that acts by deacidifying the lysosome and preventing fusion with the 
autophagosome thereby preventing formation of autolysosomes.  
Upon a 14 hour incubation with Everolimus, there is reduced green fluorescence 






fluorescence after 14 hours. Compared to the control the cells treated with chloroquine 
have increased green fluorescence, even at time point zero. After the fourteen hour 
incubation, the cells treated with chloroquine have a slightly diminished green 
fluorescence from time point zero but it is still greatly elevated compared to the control 
treated cells. (Figure 11B)  
 
 
Figure 12: Autolysosome to Autophagosome Ratio in Everolimus, Control, and Chloroquine Treated 
HBEC Cells over time. Using live cell imaging fluorescence from the GFP-mCherry labeled LC3 was 
used to quantify the autolysosomes and autophagosomes and obtain the ratios used. From this conclusions 







 Using the same fluorescent technology as in Figure 11B, we assayed autophagy 
by counting the yellow (mixture of red and green puncta) and the red puncta alone.  As 
discussed earlier presence of red puncta alone is indicative of activation of autophagy 
while yellow puncta is indicative of inhibition of autophagy. From these counts the 
autolysosome: autophagosome ratios were calculated. A greater ratio suggests a high 
level of autophagy while a ratio close to zero suggest autophagy inhibition. 
 In the HcRED cell line there was an exponential increase in the ratio of 
autolysosomes to autophagosomes upon treatment with Everolimus. There was also a 
notable linear increase in the ratio over time in the control treated cells and a very slight 
increase in the chloroquine treated cells. In the PIK3CA line there was only a slight 
difference in autolysosome:autophagosome ratio between the Everolimus and the control 
treated cells, though the ratio did increase over time in both treatments. The ratio in the 
chloroquine treated cells slightly increased over time. In the NFE2L2 line there is again 
very little difference in autolysosome:autophagosome ratio between the Everolimus and 
the control treated cells and the ratio in the chloroquine treated cells slightly increased 
over time. In the dual mutant cell line there is a significant increase in the 
autolysosome:autophagosome ratio in the Everolimus treated cells over time. However 
there is only a slight increase in the ratio in the control treated cells. In the chloroquine 
treated cells there is little change over time and the ratio remains close to zero indicating 
that autophagosomes greatly outnumber autolysosomes. (Figure 12)  







Figure 13: HBEC Clonogenic Proliferation Assay. Cells from the four lines were plated at 100 cells/mL 
and allowed to grow for 72 hours. The wells were then fixed and stained to observe colony growth. 
Proliferation in NFE2L2-HcRED and NFE2L2-PIK3CA lines were drastically reduced compared to the 
control, HcRED, and the PIK3CA line. 
 
 Early on in our investigation we performed a Clonogenic Proliferation Assay to 
determine the effect of PIK3CA and NFE2L2 on proliferation. It is well known that the 
PI3K/AKT/mTOR signaling network is a major player in cell growth and proliferation 
and often involved in tumorigenesis. We hypothesized when PIK3CA was transduced 
into the existing HBEC-NFE2L2 line, we would see increased cell prolifertation. 
However, our results were perplexing. (Figure 13) It has been well documented that the 
PI3K/AKT/mTORC1 axis increases cell proliferation. We expected the overexpression of 
NRF2 and PI3K would work synergistically to further increase cell proliferation 






necessary materials for cell growth and division as well as promote metabolic 
reprogramming to shunt glucose into anabolic pathways. In addition, research by 
Mitsuishi et al. have shown that in the presence of enhanced proliferation by active 
PI3K/AKT/mTORC1 signaling, NRF2 augments the expression of metabolic genes that 
lead to cell proliferation.2 Confoundingly, our proliferation assays showed reduced 
proliferation in both NFE2L2 transfected cell lines compared to HBEC-HcRED and 
HBEC-PIK3CA. Not only did the overexpression of NRF2 suppress proliferation in the 
HBEC-NFE2L2-HcRED line but it seemed to counteract the proliferative effects of PI3K 




















Mechanism of Synergy 
 
Figure 14: Schematic Representation of the Intersection of mTORC1 and p62. mTORC1 is a 
downstream target of the PI3K/AKT/mTOR signaling network while p62 transcription is controlled by 
NRF2. This schema shows a connection between the PI3K/AKT/mTOR and NRF2/KEAP1 pathways that 
could explain their observed cooperation.  
 Our research sought to show that NRF2/KEAP1 and PI3K/AKT/mTORC1 
pathways act synergistically to promote cancer malignancy mainly through their dual 
inhibition of autophagy. Studies into the carcinogenesis of HPV showed that the 
expression of mTOR was positively correlated with p62, a key autophagy protein. It is 
thought that increased p62 levels may play carcinogenic role in the PI3K/AKT/mTORC1 
by enhancing the activation of mTOR leading to inhibition of autophagy, increased 
proliferation, and diminished antitumor ability.36 p62 is thought to be selectively required 
for amino acid activation of mTORC1 by binding to Rag GTPase and raptor. As 






feedback loop. By this mechanism, NRF2 increases activation of the 
PI3K/AKT/mTORC1 axis and enhances the known carcinogenic properties associated 
with this axis. (Figure 14)37 
Evidence that NRF2 enhances the PI3K/AKT/mTORC1 axis was also found in 
research on PTEN and KEAP1 deficient mouse liver cells. In PTEN and KEAP1 
deficient mouse liver cells AKT and the downstream target of AKT, glycogen synthase 
kinase 3 (GSK3), were highly phosphorylated indicating robust augmentation of the 
PI3K/AKT/mTORC1 axis. Interestingly, when NRF2 function was eliminated in these 
mouse models by knocking out NFE2L2, normal phosphorylation patterns were 
completely restored. These results suggest NRF2 activation enhances the 
PI3K/AKT/mTORC1 axis. On the other hand, activation of the PI3K/AKT/mTORC1 axis 
is also thought to stabilize NRF2. Phosphorylation by AKT inactivates GSK3. However, 
active GSK3 promotes degradation of NRF2 in a KEAP1 independent manner. 
Therefore, conditions of prolonged PI3K/AKT/mTORC1 axis activation promotes the 
accumulation of NRF2.24 It is likely that both pathways act in a positive feedback loop 
with increases in one leading to increases in another and so on causing a rapid transition 
to malignancy.  
Effect of Synergy on Other Cellular Processes 
 In addition to autophagy, another cellular process in which NRF2/KEAP1 and the 
PI3K/AKT/mTORC1 axis have a synergistic effect is via the pentose phosphate pathway. 






and NADPH which is used in both nucleotide and lipid synthesis. Both ribose-5-
phosphate and NADPH are critical for highly proliferative cancer cells. In addition to 
activating cytoprotective genes, NRF2 acts as a transcription factor for genes involved in 
the pentose phosphate pathway and has been shown to promote and increase the synthesis 
of purine nucleotides. NRF2 accumulation and the PI3K/AKT/mTORC1 axis work 
synergistically to promote purine synthesis. mTORC1 serves to increase glucose uptake 
and glycolytic activity thereby increasing the supply of glycolytic intermediates to enter 
the pentose phosphate pathway. In addition, the downstream target of mTORC1, SREBP, 
regulates the enzymes of the oxidative arm of the pentose phosphate pathway, while 
NRF2 upregulates the enzymes of the pentose phosphate pathway.38  
In addition, NRF2 also augments metabolic reprogramming in cells by activating 
metabolic genes leading to the redirection of glucose and glutamine into anabolic 
pathways. The effect of NRF2 on gene expression and metabolic activities are most 
notable in the presence of active proliferative signals such as that of the 
PIK3/AKT/mTORC1 axis. The sustained activation of the PIK3/AKT/mTORC1 axis 
creates a highly proliferative environment in the cell. The functional expansion of NRF2 
in these cells enhances anabolism and further promotes the activation of the 
PIK3/AKT/mTORC1 axis. This suggests the presence of positive feedback between 
NRF2 and the PIK3/AKT/mTORC1 axis in proliferating cells. However, it should be 
noted that upregulation of NRF2 does not initiate tumorigenesis. Rather it confers 






uncontrolled proliferative properties.38 We observed reduced cell proliferation in both 
NFE2L2 transfected lines suggesting that in the early stages of tumorigenesis NRF2 may 
actually antagonize cell proliferation. 
Summary of Other Research of NRF2 and PI3K Cooperation 
Experiments done in mouse models suggest synergy between the NRF2/KEAP1 
and PI3K/AKT/mTORC1 in cancer formation. It was shown that inactivation of KEAP1 
and PTEN promotes adenocarcinoma formation in the lung. Though TSGs were not 
explored in our experiments, like NFE2L2 overexpression, KEAP1 inactivation also leads 
to constitutive activation of NRF2. Likewise, PTEN inactivation also leads to constitutive 
activation of PI3K. The loss of KEAP1 alone causes no morphological changes. 
Therefore cooperation with loss of PTEN or activation of the PI3K/AKT/mTORC1 axis 
is necessary for tumorigenesis.2  
Perturbed PI3K signaling has also been shown to increase NRF2/KEAP1 pathway 
activation. NADPH Dehydrogenase (NQO1) is a key enzyme involved in the body’s 
antioxidant response and its transcription is controlled by NRF2. Therefore NQO1 levels 
are used as biomarkers for NRF2 activation. In PTEN and KEAP1 deficient mice there 
was an synergistic increase in NQO1 compared to mice models with the loss of only one 
of these genes. This suggests that loss of PTEN increases NRF2 function in the lung by 
enhancing NRF2 stability independent of KEAP1.38  
Interpretation of Results 






The high molecular weight NRF2 antibody showed slightly increased expression 
of NRF2 in the HBEC-NFE2L2+PIK3CA line supporting our hypothesis that NRF2 and 
PI3K act synergistically. (Figure 7) In addition, probing with the PI3K antibody showed 
elevated levels of PI3K expression in the HBEC-NFE2L2+PIK3CA compared to HBEC-
PIK3CA and basal PI3K expression. (Figure 7) This suggests that both pathways act upon 
each other to increase expression. The strongest evidence from this western blot to 
support the cooperation between NRF2 and PI3K, specifically the enhancement of the 
PI3K/AKT/mTORC1 axis by NRF2, is the expression of phospho-AKT (p-AKT). (Figure 
7) AKT is a downstream target of PI3K and its phosphorylation is increased with 
elevated PI3K activity. Not only is p-AKT expression increased from basal levels in the 
HBEC-PIK3CA line but p-AKT is by far the highest in HBEC-NFE2L2+PIK3CA. This 
indicates that NRF2 via one of its effectors acts upstream of AKT to increase 
phosphorylation and therefore increase the detectable amount of p-AKT. Total AKT, 
which includes both the phosphorylated and non-phosphorylated forms of AKT, was also 
probed to verify that the concentration of total AKT was the same across the four cell 
lines and to give validity to our results for p-AKT. (Figure 7)  
 As discussed earlier the synergy between constitutively active NRF2 and the 
PI3K/AKT/mTORC1 axis can be explained by the enhanced transcription of p62 which 
activates mTORC1 via the same mechanism as nutrient sensing. However AKT is 
upstream of mTORC1 and its enhanced phosphorylation in the presence of constitutively 






role of hepatomegaly, the abnormal enlargement of the liver, suggest NRF2’s 
transcriptional control over EGFR ligands, as a possible explanation for the elevated p-
AKT levels we observed.39 Upon binding to their ligand EGFR dimerize and activate 
PI3K which leads to downstream phosphorylation of AKT. Increased transcription of 
EGFR ligands lead to increased EGFR dimerization and PI3K activation. Due to the 
compounding effect of signal transduction even a small increase in PI3K can lead to big 
increase in activation of downstream targets explaining the huge increase in p-AKT when 
constitutively active PI3K and NRF2 are combined. As mTORC1 is a downstream target 
of PI3K/AKT, increased transcription of EGFR ligands by constitutively active NRF2 is 
another mechanism by which NRF2 acts synergistically with PI3K to inhibit autophagy.  
Western Blots for Autophagy Markers 
 As shown in Figure 8, ATG5 levels were not elevated from basal levels shown by 
HBEC-HcRED in the sample taken from HBEC-PIK3CA line but were elevated in the 
HBEC-NFE2L2-HcRED sample. ATG5 levels were the highest in HBEC-NFE2L2-
PIK3CA indicating that NRF2 and PI3K act synergistically to inhibit autophagy as the 
increase in ATG5 levels cannot be explained by summing the increase in ATG5 levels in 
HBEC-PIK3CA and HBEC-NFE2L2-HcRED since the level of ATG5 observed in 
HBEC-PIK3CA is not increased from baseline. The unchanged levels of ATG5 in cells 
only transfected with PIK3CA does not reflect autophagy activation in this line because 
the PI3K/AKT/mTORC1 axis mainly inhibits autophagy via phosphorylation of ATG13 






ATG5-ATG12. The antibody for ATG5 is for the ATG5-ATG12 and therefore does not 
provide a good marker for autophagy in the PIK3CA line. The increased ATG5 levels in 
the HBEC-NFE2L2+PIK3CA but not HBEC-PIK3CA can be explained by the 
PI3K/AKT/mTORC1 axis enhancing NRF2 activation by phosphorylating GSK3 thus 
preventing NRF2 degradation.  
 
 Levels for LC3 in Figure 8 were only found to be elevated in the HBEC-
NFE2L2+PIK3CA dual mutant line. LC3 transcription is enhanced by high ROS levels.26 
The LC3 antibody used was for the LC3B-II, the processed form of LC3. The processing 
of LC3 to LC3B-II is dependent on autophagy activation and the formation of the ATG5-
ATG12 complex. Though autophagy may be inhibited from basal levels in the HBEC-
PIK3CA line, like with our results for ATG5 it is not observed because the 
PI3K/AKT/mTORC1 inhibits autophagy pre-ATG5-ATG12 complex formation. Since 
constitutive activation of NRF2 drastically reduces ROS levels, LC3 transcription is 
reduced. This explains why LC3 levels in the HBEC-NFE2L2-HcRED samples are not 
elevated from baseline even though we expect autophagy to be inhibited in this line. LC3 
levels are elevated in the HBEC-NFE2L2+PIK3CA dual mutant samples. This result 
indicates that the inhibition of autophagy when both NRF2 and PI3K are constitutively 
active is greater than when either mutant protein is present on its own thus supporting our 






 Our results for p62 in Figure 8 were unexpected. While p62 accumulation was 
observed in the lines transfected with PIK3CA indicating reduced autophagy, its 
expression was reduced in lines transfected with NFE2L2, with its expression being 
lower in the HBEC-NFE2L2-HcRED line than even the control, HBEC-HcRED. In 
addition, p62 levels in HBEC-NFE2L2+PIK3CA were lower than in HBEC-PIK3CA 
suggesting that NRF2 expression counteracts the effect of the PI3K/AKT/mTORC1 axis 
on p62 accumulation. As discussed in the introduction section, this is surprising as p62 is 
a transcriptional target of NRF2. Increased NRF2 levels should increase p62 expression. 
One possible explanation for our observations is the interaction between KEAP1 and p62. 
Studies by Tian and Liu have shown that NRF2 activity is positively correlated with 
KEAP1 mRNA expression in squamous cell carcinomas. By using NRF2 activating drugs 
tBHQ and dimethylformamide on NRF2 deficient human lung cell line H292, Tian and 
Liu showed that KEAP1 mRNA expression increased. They also showed that KEAP1 
mRNA expression is downregulated when NRF2 addicted human lung carcinoma line 
A549 is treated with NRF2 siRNA. The proposed mechanism for NRF2-driven 
transcription of KEAP1 is an ARE-sequence in KEAP1’s promoter region.40,41 Since p62 
binds to KEAP1 and leads to the degradation of the complex, this would lead to 
decreased p62 levels in the NFE2L2 transfected lines due to the increase in KEAP1 for 
p62 to bind to.  






 P-S6 is a downstream target of mTORC1 and as expected we observed decreased 
expression in the presence of a mTORC1 inhibitor. In Figure 9, we observed increased P-
S6 expression in the control samples of the PIK3CA, NFE2L2, and dual mutant lines. 
Since both the PIK3CA and the dual mutant contain an oncogenic, constitutively active 
form of PI3K elevated P-S6 levels were expected. This also explains the dose 
dependency observed in these samples in Figure 9. With more mTORC1 activated by the 
mutant PI3K, more Everolimus is needed to inhibit the additional complexes and reduce 
P-S6 levels. However, the elevated P-S6 levels were not expected for the sample from the 
NFE2L2 transfected line. This result can be explained by the cooperation of the 
NRF2/KEAP1 and PI3K/AKT/mTORC1 pathways via p62. Constitutively active NRF2 
leads to increased transcription of p62. After translation, p62 can activate mTORC1 and 
lead to increased P-S6 levels.  
 Expression of P-S6K, another downstream target of mTORC1, is reduced beyond 
detectable levels in all Everolimus treated samples in Figure 9.  We also observed 
increased P-S6K expression in the control samples of the PIK3CA, NFE2L2, and dual 
mutant lines in this figure. The highest P-S6K level was observed in the control sample of 
the dual mutant, supporting the proposed synergy between the NRF2/KEAP1 and 
PI3K/AKT/mTORC1 pathways. The elevated levels of P-S6K in the dual mutant and 
NFE2L2 line can again be explained by the linkage of the two pathways through p62.  
 As expected, LC3 levels were low in the three HcRED samples in Figure 9. 






restore it. In the PIK3CA sample LC3 levels are elevated in the control sample and 
reduced in the Everolimus treated samples. These results differ from our results from the 
Western Blot for autophagy markers (Figure 8) that did not show increased LC3 levels in 
the PIK3CA line. One possible explanation is that we performed the Everolimus Western 
Blot months after the one performed for the autophagy markers. Oncogenes such as 
PIK3CA are toxic to cells. Increased activity of PI3K or its downstream targets may 
activate pathways in the cell to counteract the upregulation in the PI3K/mTORC1/AKT 
axis. For example, increased levels of PIP3, the product of PI3K, recruits more PTEN to 
the plasma membrane causing downregulation of the PI3K/mTORC1/AKT axis.42 In 
addition, studies have shown that PTEN not only prevents AKT from being 
phosphorylated but also participates in the complex that marks P-AKT for degradation 
when P-AKT levels are high. However, the protective capacity of these cellular feedback 
mechanisms are finite. Eventually the constitutive activation of the PI3K/AKT/mTORC1 
pathway will exceed the buffering ability of the cell. Perhaps enhanced PI3K signaling 
was buffered in earlier passages and autophagy remained active, preventing the 
accumulation of LC3 as seen in the Western Blot for the autophagy markers. A Western 
Blot for LC3 should be repeated to confirm our results. LC3 levels are also elevated in 
NFE2L2 transfected line and do not vary between the control, 1mM and 2mM 
Everolimus treated cells as shown in Figure 9. This shows that mTORC1 inhibition has 
no effect on mitigating autophagy inhibition in this line. Since NRF2 inhibits autophagy 






effect on the NFE2L2 cell line. Interestingly, in the dual mutant line LC3 is elevated in 
the control, reduced in the 1mM Everolimus sample, and further reduced to near basal 
levels in the 2mM sample. The LC3 level in the dual mutant 2mM treated sample is 
lower than in PIK3CA suggesting that transfection with both NFE2L2 and PIK3CA 
oncogenes makes the cell more sensitive to mTORC1 inhibitors which could have 
important clinical implications. The reason for this increased sensitivity could lie in the 
p62 linkage between the two pathways. p62 is a transcriptional target of NRF2 but p62 
also enhances transcription of NRF2 and activates mTORC1. Upon treatment with 
Everolimus, mTORC1 inhibition of autophagy is removed. Without input from this major 
player, autophagy is at least partly restored and a considerable amount of p62 is degraded 
in the autolysosome. This has major effects on activating autophagy as not only is 
transcription of NRF2 is reduced but activation of mTORC1 by p62 is also reduced.  
This explanation is supported by our Western Blot for p62 that shows reduced 
p62 levels in the 1mM and 2mM Everolimus treated samples. (Figure 9) The Western 
blot for p62 also shows the NFE2L2 transfected line is resistant to mTORC1 as the p62 
levels were elevated from baseline but unchanged across the three sample conditions. The 
PIK3CA transfected line showed reduced p62 levels in only the 2mM but not the 1mM 
Everolimus treated line suggesting dose dependence.   
Everolimus IC50 
 By calculating the IC50 of Everolimus on each cell line, we determined that 






control HBEC-HcRED had the least. (Figure 10) From these results we can conclude that 
NRF2 and PI3K act synergistically on the cell cycle and proliferation since the 
Everolimus had by far the greatest effect on reducing proliferation in the HBEC-
NFE2L2-PIK3CA line.   
Response of HBEC-HcRED cells to Everolimus, DMSO, and Chloroquine 
  Despite being unable to acquire clear images for the PIK3CA, NFE2L2 or dual 
mutant lines due to oncogenic toxicity, the images acquired for HcRED exemplify the 
expected effect of these drugs on HBEC. In the Everolimus treated cells displayed in 
Figure 11, there is significant yellow fluorescence at time point zero. After a fourteen 
hour incubation, the green fluorescence is quenched and more cells appear red while less 
cells appear yellow. This indicates that Everolimus is activating autophagy as there are 
less autophagosomes present as shown by reduced yellow fluorescence. Presumably, 
more autophagosomes are fusing with lysosomes to become autolysosomes as there 
appears to be more cells that appear only red.  
In the control (DMSO) treated cells there is a slight decrease in green 
fluorescence after a 14 hour incubation as compared to time point zero. (Figure 11) This 
is an unexpected result as we predicted there should be no change in autophagy in the 
control cells over time. The green fluorescence from GFP has been known to degrade 
over time and presents a confounding effect on interpreting the significance of our 






experiment. It is possible that overtime the cells became nutrient deprived and the 
reduction in green fluorescence is a result of the initiation of autophagy.  
The chloroquine treated cells display increased yellow fluorescence even at time 
point zero in Figure 11. As expected, chloroquine potently inhibited autophagy as the 
accumulation of yellow fluorescence indicates the failure of the autophagosome and 
lysosome to fuse. However, after the fourteen hour treatment the yellow fluorescence is 
slightly decreased. Again, this is likely due to the degradation of the green fluorescent 
signal or an induction of autophagy due to unintentional nutrient deprivation.  
Autolysosome to Autophagosome Ratio in Everolimus, Control, and Chloroquine Treated 
Cells  
 
As shown in Figure 12, Everolimus treated cells in the HcRED line has an 
exponential increase in the autolysosome:autophagosome over time indicating that 
autophagy is overactivated. In the absence of an autophagy inhibiting oncogene, 
induction of autophagy by Everolimus has the greatest effect on the HcRED line as there 
is no counteraction by the products of mutant PIK3CA or NFE2L2. (Figure 12) In the 
PIK3CA and NFE2L2 HBEC lines there is elevated autolysosome:autophagosome 
compared to the dual mutant. However, in the dual mutant the increase in the ratio in the 
Everolimus treated cells is significantly elevated about the increase in the ratio in the 
control cells while the increase in the ratio over time is almost equal between the 
Everolimus and control treated cells as shown in Figure 12. Though the dual mutant does 
not have a high baseline autolysosome:autophagosome compared to the PIK3CA and 






indicate these cells are more sensitive to mTORC1 inhibitors. It is also interesting that the 
increase in autophagy in these cells does not become quantifiable in Figure 12 until 
approximately 4-5 hours after treatment with Everolimus. This is consistent with our 
understanding that mTORC1 inhibitors change transcriptional activity in the cell and 
therefore their effects have a significant lag time post treatment.  
The dual mutant has the greatest inhibition of autophagy under control conditions 
as shown by its low autolysosome:autophagosome in the DMSO treated cells which 
suggests an accumulation of autolysosomes. However, there is a slight increase in the 
ratio in the control treated cells of the dual mutant. In the other cell lines this increase is 
even more pronounced. (Figure 12) This is likely attributable to activation of autophagy 
caused by nutrient depletion. The increase in autophagy is more observable in the 
HcRED, PIK3CA, and the NFE2L2 than the dual mutant because of confluence of the cell 
lines. Despite allowing the cells to incubate for 48 hours after plating,  the dual mutant 
cells did not grow to confluence likely due to reduced proliferation from the combined 
oncogenic toxicity from PIK3CA and NFE2L2. Due to the differences in confluence the 
cell lines had different nutritional needs and autophagy was activated sooner in the 
control treated cells of the more confluent lines.  
The autolysosome:autophagosome in chloroquine treated cells starts close to zero 
in all the cell lines indicating a stark inhibition of autophagy. However, in all the cell 
lines despite the dual mutant there is a gradual increase in autolysosome:autophagosome 






high concentration, is fleeting and autophagy will begin to recover in the cells as soon as 
3 hours post-treatment. In the dual mutant this is not observed, likely because the baseline 
ratio is already extremely low.  
Clonogenic Proliferation Assay  
 One possible explanation for the perplexing results observed in Figure 13 is the 
increased clearance of ROS that accompany the overexpression of NRF2. ROS were once 
considered to only be harmful carcinogenic compounds that lead to cell damage and 
dysfunction. However, it is now thought that ROS have a physiological role as signal 
mediators involved in regulating important cellular functions such as cell proliferation 
and differentiation. For example, in murine models it has been shown that 
osteoclastogenesis is regulated by intracellular ROS, including H₂O₂. Elevated NRF2 
levels in these models inhibit osteoclastogenesis by reducing ROS levels.43 It is possible 
that a similar mechanism is at play in the NFE2L2 and dual mutant lines. 
 Another explanation for the reduced growth in the mutant NFE2L2 transduced 
lines is oncogene-induced senescence (OIS). Though oncogenes are thought to promote 
cell proliferation, hyperactivation of certain pathways can actually be toxic. OIS protects 
against this oncogenic stress by restricting proliferation of abnormal cells. However, OIS 
also has been shown to promote tumorigenesis by enhancing angiogenesis, metastasis, 
and promoting the formation of cancer stem cells.44,45 OIS has also been linked to 
reducing the efficacy of cancer therapeutics.46,47 Induction of OIS by oncogenic NFE2L2 






 Though we hypothesize that oncogenic driver mutations in PIK3CA and NFE2L2 
would act synergistically to transform pre-malignant NSCLC lesions, from this 
experiment it is evident that they do not do this by augmenting cell proliferation, at least 
not in the initial stages of tumorigenesis. This experiment led us to focus greater attention 
on other pathways of intersection between PIK3CA and NFE2L2, specifically autophagy.  
Global Implications of Research and Next Steps 
 Understanding how early mutations in pre-malignant  LSCC lesions act 
synergistically to promote metastasis has many potential benefits for enhancing early 
detection and improving cancer therapeutics. By identifying the proteins and cellular 
processes involved in this transformation by creating HBEC models we have established 
several targets for screening and drug research. Currently, over half of all lung cancers 
are detected in stage IV once clinical manifestations such as cough, dyspnea, and chest 
pain emerge.48 This explains the mere 23.6% five year survival rate for  LSCC.49 Given 
this poor prognosis at late stage diagnosis there is strong interest in improving early 
detection of  LSCC.  Our results have identified autophagy as a pathway affected early in 
tumorigenesis as early oncogenic mutations in NFE2L2 and PIK3CA work synergistically 
to inhibit autophagy. However, currently methods to quantitate autophagic flux in 
animals require tissue isolation. Our results support the need to develop non-invasive 
screening procedures to quantitate changes in autophagic flux by detecting autophagy 
biomarkers. This could be done by detecting circulating factors regulated by autophagy 






one potential approach to quantitating the abundance of target autophagy markers. PET is 
a nuclear imaging technology in which a small radioactive ligand is injected 
intravenously. The ligand then binds to the target molecule and the gamma rays released 
from the ligand-target complex is then read by the PET scanner. This gives a direct 
measurement of the target abundance.49 From our results, LC3 would be a good target 
molecule for detection of autophagy by PET since it drastically accumulates in cells 
where autophagy is inhibited.  
 There are several experiments that could be performed to confirm our results and 
further support our hypothesis. One such experiment is a Western blot to probe for 
KEAP1 levels. As discussed, it has been demonstrated that elevated NRF2 levels create 
negative feedback loop by increasing transcription of KEAP1 mRNA and thereby 
promoting the creation of more KEAP1 to sequester NRF2 and inhibit its activity. This is 
a mechanism by which the constitutively active form of NRF2 mediates its oncogenic 
activity and delays tumorigenesis. It is important to verify whether this mechanism 
occurs in HBEC-NFE2L2 transfected lines as it would explain the inhibition of 
proliferation observed in those lines. In addition, p62, the major link discussed between 
the NRF2-KEAP1 and PI3K/AKT/mTORC1 pathways,  binds to KEAP1 and marks it for 
degradation. Elevated levels of KEAP1 would limit the levels free p62 available to 
activate mTORC1 thereby decreasing autophagy inhibition. This presents an argument 
against the cooperation of NRF2 and PI3K/AKT/mTORC1 pathway and further research 






 Relatedly, we proposed p62 as the major mechanism of synergy between 
NRF2/KEAP1 and PI3K/AKT/mTORC1 pathway to explain the increase in autophagy 
we observed. Further experiments are needed to verify p62’s role in the cooperation of 
these pathways. Post transcriptional gene silencing using small interfering RNA (siRNA) 
is often used to research the roles of certain proteins on various cellular processes as it 
allows researchers to knock-out the expression of certain proteins without altering the 
genome of their cell lines. siRNA are double stranded RNA molecules that enter cells via 
transfection. They are then processed and the lagging strand is degraded inside the cell 
while  the leading strand associates with the RNA-induced silencing complex (RISC). 
When this complex comes in contact with the mRNA of the target gene, base pairing 
between the leading strand and the mRNA occurs. The target mRNA is then cleaved and 
is rendered untranslatable thus silencing protein expression.50 When silencing p62 
expression in our cell lines we would expect autophagy inhibition to decrease as shown 
by decreased expression of ATG5 and LC3 on a western blot as well as decreased 
phosphorylation of mTORC1 targets as there would be decreased activation of mTORC1 
by p62. Effectively silencing p62 should restore autophagy in the HBEC-
NFE2L2+PIK3CA thereby preventing tumorigenesis. Regarding global implications, in 
recent years there has been much interest and research into the use of siRNA 
encapsulated in liposomes clinically in cancer treatment. If the expected results in this 
potential experiment were observed, this would support the use of p62 siRNA in the 






  In this thesis, we explored cooperation of PIK3CA and NFE2L2 in HBEC cell 
lines and there are many opportunities to further our research by exploring the 
cooperation of other oncogenes in LSCC. A logical next step after verifying our results, 
would be to investigate how additional mutations affect tumorigenesis when transfected 
in the PIK3CA and NFE2L2 cell lines alone and when transfected into the PIK3CA and 
NFE2L2 dual mutant cell line. The obvious selection for the third gene to study is TP53 
as it was found to co-occur with PIK3CA at a statistically significant rate. TP53 is a 
tumor suppressor gene and is  the most commonly mutated gene in human cancer. Out of 
our samples from the Pan Cancer Atlas data set 86% contained a mutation in TP53. TP53 
encodes the p53 protein,  transcription factor, which activates autophagy by promoting 
the transcription of autophagy related genes such as damage-regulated autophagy 
modulator (DRAM), ISG20L1, and ULK1.51 Downstream targets of p53 have been shown 
to interact with the PI3K/AKT/mTORC1 axis by inhibiting the mTOR complex.33 By 
knocking out p53 expression, autophagy is expected to decrease. The question to be 
answered in future studies are whether oncogenic PIK3CA expression cooperates with the 
knock-out of TP53 to inhibit autophagy and whether knocking out TP53 in the NFE2L2-
PIK3CA dual mutant lines has a greater effect on the inhibition of autophagy than would 
be expected.  
Another possible third gene target is KRAS. KRAS is an oncogene that commonly 
arises in early pre-neoplastic adenocarcinoma lesions at a prevalence of 33% but was not 






with PIK3CA and NFE2L2 at a statistically significant rate.32,52 Though it is apparent that 
KRAS mutations do not occur in LSCCs in vivo, creation of a KRAS + PIK3CA + 
NFE2L2 mutant would provide important information about the role of autophagy in 
LSCC. PIK3CA and NFE2L2 act synergistically to promote initiation of tumorigenesis by 
inhibiting autophagy. However, as the tumor develops autophagy must be promoted for 
further progression as the cells become more dependent on autophagy to sustain their 
metabolic needs due to changes in their metabolism. Being able to mark the transition 
from reduced autophagy to enhanced autophagy in a LSCCs has many clinical 
implications. For example drugs that may work in the early stages of LSCCs to restore 
the reduced autophagy, such as mTORC1, may actually promote tumorigenesis once the 
tumor switches to autophagy dependence. KRAS activation changes the metabolism of 
the cell by suppressing acetyl-CoA production thereby increasing the cell’s dependence 
on autophagy. Inhibition of autophagy in KRAS mutant cells causes robust tumor 
suppression due reduced mitochondrial oxidative phosphorylation and lack of an energy 
source. As inhibition of autophagy causes damage to DNA and leads to additional 
mutations a possible experiment would be to transfect KRAS into the cell lines at different 
time points. At the initial time points it could be hypothesized that the addition of KRAS 
would inhibit tumorigenesis in the PIK3CA+NFE2L2 line as it is autophagy addicted and 
the reduced autophagy in this line would send the cells into metabolic crisis. However 
over time as the PIK3CA+NFE2L2 line acquired more mutations the transfection of 










Figure 15: Schematic Representation of the effect of ROS on Autophagy. Presence of ROS increase the 
activity of several transcription factors including NRF2 that regulate autophagy and apoptosis. 
Upregulating antioxidant gene expression through activation of NRF2 leads to inhibition of autophagy.  
 Both the NRF2-KEAP1 pathway and autophagy are cellular stress responses. 
Both serve to reduce oxidative stress and ROS levels. NRF2 reduces ROS levels by 
increasing transcription of components of the glutathione and thioredoxin antioxidant 
systems while autophagy reduces ROS levels by digesting damaged mitochondria. 
(Figure 15)53 Accumulation of NRF2 when autophagy is deficient causes disruptions in 
redox homeostasis.17,25 Constitutive activation of NRF2 disrupts autophagy by 
eliminating ROS. Studies have shown that the presence of ROS initiate autophagosome 
formation and increase the rate of autophagic degradation by activating transcription 






or constitutively active, ROS species are eliminated to levels below baseline and 
autophagy is inhibited.53,55  
 To proceed with our research it is imperative that we further understand the 
mechanisms by which free radicals activate autophagy. To further elucidate these 
mechanisms acetylcysteine, an antioxidant and precursor to reduced glutathione, could be 
used to treat the cells. This would quench the ROS thereby mimicking NRF2 activation. 
We would expect autophagy to see autophagy inhibition in the HcRED line and a further 
inhibition in the oncogenic lines. We could also add free radicals to the cell lines and see 
if we observed an increase in autophagy to confirm if ROS are truly an activator of 
autophagy as the scientific literature suggests. 
Overall, the cooperation between NRF2 and PI3K/AKT/mTORC1 signaling in 
inducing the malignant evolution of cancers is not just of interest for modeling  LSCC 
development. Understanding the synergy between these two pathways could provide 
great insight for development of therapeutics. An effective cancer therapy could be found 
by disrupting feedback activation--Inhibitors of PI3K/AKT/mTORC1 signaling could 
weaken NRF2 activity, while a therapeutic design to mimic KEAP1 and sequester NRF2 
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